Strategic Planning

opportunity for patients to conveniently receive an injection that can significantly improve their life quality is unmatched. The improvement in polyneuropathy symptoms allows for patients to maintain independence in ambulation and other activities of daily living. Although the retail cost of vutrisiran is high, the manufacturer provides several patient assistance programs that allow patients to obtain the medication at a lower cost5. Overall, vutrisiran should be considered as a safe, effective, and tolerable option for the treatment of polyneuropathy in patients with hATTR.

At the time of authorship, Dr. Madison Abbs is a PGY-1 Pharmacy resident at UPMC St. Margaret and can be reached at abbsmc@ upmc.edu. Dr. Arianna Sprando is a PGY-2 Ambulatory Care/Family Medicine resident at UPMC St. Margaret. Dr. Heather Sakely, PharmD, BCPS, BCGP, provided editing and mentoring for this article and can be reached at sakelyh@upmc.edu.

References

1. Keam S. J. (2022). Vutrisiran: First Approval. Drugs, 82(13), 1419–1425. https://doi.org/10.1007/s40265-022-01765-5

2. Hereditary ATTR Amyloidosis. Cambridge, MA: Alnylam Pharmaceuticals, Inc. hATTR Amyloidosis—A Rapidly Progressive, Multisystem Disease

3. Habtemariam BA, Karsten V, Attarwala H, et al. Single-Dose Pharmacokinetics and Pharmacodynamics of Transthyretin Targeting N-acetylgalactosamine-Small Interfering Ribonucleic Acid Conjugate, Vutrisiran, in Healthy Subjects. Clin Pharmacol Ther. 2021;109(2):372-382. doi:10.1002/ cpt.1974

4. Adams, D., Tournev, I. L., Taylor, M. S., Coelho, T., PlantéBordeneuve, V., Berk, J. L., González-Duarte, A., Gillmore, J. D., Low, S. C., Sekijima, Y., Obici, L., Chen, C., Badri, P., Arum, S. M., Vest, J., Polydefkis, M., & HELIOS-A Collaborators (2022). Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial. Amyloid: the international journal of experimental and clinical investigation: the official journal of the International Society of Amyloidosis, 1–9. Advance online publication.

5. AMVUTTRA Prescribing Information. Cambridge, MA: Alnylam Pharmaceuticals, Inc.

6. Onpattro (patisiran) [prescribing information]. Cambridge, MA: Alnylam Pharmaceuticals Inc; May 2021.